Professor Richard Neal's team at the University of Exeter just released results that offer a glimmer of hope for one of medicine's most pressing challenges: catching cancer before it becomes incurable. Over three years, more than 142,000 volunteers aged 50–77 across eight regions of England participated in the NHS Galleri trial, a landmark study testing whether a simple blood test could detect cancer earlier than existing screening methods.
The Galleri blood test works by identifying a "signal" shared by many different types of cancer in a person's blood—a molecular fingerprint that reveals the disease's presence long before traditional methods might catch it. Participants provided three blood samples over two years, allowing researchers to track whether the test could spot cancers at an earlier, more treatable stage. The question mattered deeply: cancer outcomes shift dramatically depending on when diagnosis occurs. A stage 4 cancer diagnosis often means discussing palliative care, while the same cancer caught at an earlier stage might be curable.
The trial did not meet its primary goal. Researchers found no significant overall reduction in the combined number of stage 3 and stage 4 cancers diagnosed between those who received the blood test and those who did not. Yet buried in the data was something remarkable. Among people who had the blood test, at least 20% fewer advanced stage 4 cancers were diagnosed in the second and third rounds of screening. The effect actually strengthened by the third year, suggesting the test's value may grow with repeated use. Professor Charles Swanton, a thoracic medical oncologist at University College London Hospital and co-investigator, explained why this matters: "For many cancers there is a real gulf in outlook between a stage 4 diagnosis and one caught earlier. The hope is that for more patients, the conversation can be about treating cancer with curative intent rather than managing it palliatively."
This distinction captures something profound about early detection. Stage 4 cancers—those that have spread to distant organs—carry the bleakest prognoses across most cancer types. A 20% reduction in these diagnoses translates to thousands of people annually who might avoid conversations about end-of-life management and instead discuss curative treatment options. For lung cancer, pancreatic cancer, ovarian cancer, and others, that difference can be the difference between hope and resignation.
The researchers emphasized this is just the beginning. The NHS Galleri trial is the largest of its kind, and Professor Neal said researchers will continue analyzing the data for months and years to come. Future results may reveal additional benefits, clarify which cancer types the test detects most effectively, or show how regular screening with the blood test changes outcomes over longer timelines. The trial's scale—more than 142,000 participants—makes it a genuinely historic study in cancer research, and the data it generates will likely inform NHS policy and clinical practice across the world.
What the trial proved is that a simple blood test can nudge cancer diagnosis earlier for some of the most dangerous presentations. That's not the comprehensive victory researchers initially hoped for, but in oncology, incremental progress toward catching stage 4 cancers before they develop is progress worth celebrating.